Ken Griffin Agenus Inc Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$0.53 - $0.93 $109,021 - $191,301	205,700 Added 53.33%	591,400 $343,000
Q4 2023 Feb 14, 2024	BUY	$0.63 - $1.14 $21,483 - $38,874	34,100 Added 9.7%	385,700 $320,000
Q3 2023 Nov 14, 2023	BUY	$1.12 - $1.88 $80,864 - $135,736	72,200 Added 25.84%	351,600 $397,000
Q2 2023 Aug 14, 2023	BUY	$1.31 - $2.04 $3,144 - $4,896	2,400 Added 0.87%	279,400 $447,000
Q1 2023 May 15, 2023	SELL	$1.45 - $2.95 $40,890 - $83,190	-28,200 Reduced 9.24%	277,000 $421,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $3.25 $108,676 - $174,850	-53,800 Reduced 14.99%	305,200 $732,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.14 $37,828 - $60,602	-19,300 Reduced 5.1%	359,000 $736,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.